Research Article
A Novel Inflammation-Based Stage (I Stage) in Patients with Resectable Esophageal Squamous Cell Carcinoma
Table 3
Univariate analyses for patients with ESCC.
| | 5-year CSS (%) | value | HR (95% CI) | value |
| Age (years) | | 0.978 | | 0.978 | ≤60 | 30.1 | | 1.000 | | >60 | 33.6 | | 0.996 (0.762–1.302) | | Gender | | 0.322 | | 0.327 | Female | 38.1 | | 1.000 | | Male | 30.6 | | 1.227 (0.815–1.848) | | Tumor length (cm) | | 0.003 | | 0.004 | ≤3 | 41.6 | | 1.000 | | >3 | 27.8 | | 1.580 (1.157–2.157) | | Tumor location | | 0.556 | | 0.564 | Upper | 41.2 | | 1.000 | | Middle | 33.1 | | 0.735 (0.385–1.404) | 0.351 | Lower | 29.0 | | 0.908 (0.693–1.190) | 0.483 | Differentiation | | 0.198 | | 0.207 | Good | 38.6 | | 1.000 | | Moderate | 31.0 | | 1.185 (0.786–1.786) | 0.417 | Poor | 28.6 | | 1.504 (0.933–2.424) | 0.098 | Vessel involvement | | 0.007 | | 0.008 | Negative | 34.1 | | 1.000 | | Positive | 18.9 | | 1.577 (1.129–2.202) | | Perineural invasion | | 0.005 | | 0.006 | Negative | 35.0 | | 1.000 | | Positive | 17.5 | | 1.551 (1.135–2.119) | | TNM stage | | <0.001 | | <0.001 | I | 51.9 | | 1.000 | | II | 32.7 | | 1.878 (1.269–2.780) | 0.002 | III | 18.8 | | 2.943 (2.039–4.248) | <0.001 | I stage | | <0.001 | | <0.001 | I0 | 50.0 | | 1.000 | | I1 | 30.9 | | 1.696 (1.189–2.420) | 0.004 | I2 | 18.2 | | 2.676 (1.837–3.900) | <0.001 | I3 | 8.3 | | 4.372 (2.924–6.536) | <0.001 | Adjuvant therapy | | 0.398 | | 0.402 | No | 32.0 | | 1.000 | | Yes | 30.6 | | 1.130 (0.849–1.504) | | CRP (mg/L) | | <0.001 | | <0.001 | ≤10.0 | 39.2 | | 1.000 | | >10.0 | 17.1 | | 2.217 (1.692–2.906) | | NLR | | <0.001 | | <0.001 | ≤3.5 | 39.0 | | 1.000 | | >3.5 | 17.7 | | 1.925 (1.471–2.519) | | PLR | | <0.001 | | <0.001 | ≤150 | 43.9 | | 1.000 | | >150 | 17.3 | | 2.260 (1.729–2.955) | |
|
|